Arrestins Come of Age: A Personal Historical Perspective - Progress in Molecular Biology and Translational Science - page 15

50. Coffa S, BreitmanM, Spiller BW, Gurevich VV. A single mutation in arrestin-2 prevents
ERK1/2 activation by reducing c-Raf1 binding. Biochemistry . 2011;50:6951 - 6958.
51. Xiao K, McClatchy DB, Shukla AK, et al. Functional specialization of b -arrestin inter-
actions revealed by proteomic analysis. Proc Natl Acad Sci USA . 2007;104:12011 - 12016.
52. Xiao K, Sun J, Kim J, et al. Global phosphorylation analysis of b -arrestin-mediated sig-
naling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci USA .
2010;107:15299 - 15304.
53. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. b -Arrestins and cell signaling. Annu Rev
Physiol . 2007;69:483 - 510.
54. Kenakin T. Functional selectivity through protean and biased agonism: who steers the
ship? Mol Pharmacol . 2007;72:1393- 1401.
55. Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching old receptors new tricks: biasing
seven-transmembrane receptors. Nat Rev Drug Discov . 2010;9:1 - 12.
56. Kahsai AW, Xiao K, Rajagopal S, et al. Multiple ligand-specific conformations of the
b 2-adrenergic receptor. Nat Chem Biol . 2011;7:692 - 700.
57. Seifert R, Gether U, Wenzel-Seifert K, Kobilka BK. Effects of guanine, inosine, and
xanthine nucleotides on b 2-adrenergic receptor/G(s) interactions: evidence for multiple
receptor conformations. Mol Pharmacol . 1999;56:348 - 358.
58. West GM, Chien EY, Katritch V, et al. Ligand-dependent perturbation of the confor-
mational ensemble for the GPCR b 2-adrenergic receptor revealed by HDX. Structure .
2011;19:1424- 1432.
59. Whalen E, Rajagopal S, Lefkowitz RJ. The therapeutic potential of b -arrestin and
G protein-biased agonists. Trends Mol Med . 2011;17:126 - 139.
60. Zidar DA, Violin JD, Whalen EJ, Lefkowitz RJ. Selective engagement of G protein-
coupled receptor kinase (GRKs) encodes distinct functions of biased ligands. Proc Natl
Acad Sci USA . 2009;106:9649- 9654.
61. Rajagopal S, Kim J, Ahn S, et al. b -Arrestin-but not G-protein-mediated signaling by
the “decoy” receptor CXCR7. Proc Natl Acad Sci USA . 2010;107:628- 632.
62. Rajagopal K, Whalen EJ, Violin JD, et al. b -Arrestin2-mediated inotropic effects of the
angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci USA .
2006;103:16284 - 16289.
63. Ahn S, Kim J, Hara MR, Ren X-R, Lefkowitz RJ. b -Arrestin-2 mediates anti-apoptotic
signaling through regulation of BAD phosphorylation. JBiolChem . 2009;284:8855 - 8865.
64. Boerrigter G, Lark MW, Whalen EJ, Soergel DG, Violin JD, Burnett Jr JC. Cardiorenal
actions of TRV120027, a novel b -arrestin-biased ligand at the angiotensin II type
I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart
failure. Circ Heart Fail . 2011;6:770 - 778.
65. Violin JD, DeWire SM, Yamashita D, et al. Selectively engaging b -arrestins at the angio-
tensin II type 1 receptor reduces blood pressure and increases cardiac performance.
J Pharmacol Exp Ther . 2010;335:572 - 579.
66. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MD, Lin F-T. Enhanced
morphine analgesia in mice lacking b arrestin-2. Science . 1999;286:2495- 2498.
67. Raehal KM, Walker JK, Bohn LM. Morphine side effects in b -arrestin 2 knockout mice.
J Pharmacol Exp Ther . 2005;314:1195 - 1201.
68. Xiao K, Shenoy SK, Nobles K, Lefkowitz RJ. Activation dependent conformational
changes in b -arrestin2. J Biol Chem . 2004;279:55744 - 55753.
69. Nobles KN, Ziqiang G, Kunhong X, Oas TG, Lefkowitz RJ. The active conformation
of b -arrestin1: direct evidence for the phosphate sensor in the N-domain and conforma-
tional differences in the active states of b -arrestins1 and 2. J Biol Chem . 2007;282:
21370 - 21381.
70. Shukla AK, Violin JD, Whalen EJ, Gesty-Palmer D, Shenoy SK, Lefkowitz RJ. Distinct
conformational changes in b -arrestin report biased agonism at seven-transmembrane
receptors. Proc Natl Acad Sci USA . 2008;105:9988 - 9995.